FIELD: medicine.
SUBSTANCE: invention relates to new peptides, their pharmaceutical compositions and use for relief or prevention of neurodegenerative diseases.
EFFECT: technical result is obtaining modified peptides for use in the treatment of neurodegenerative diseases.
16 cl, 29 dwg, 3 tbl, 7 ex
Title | Year | Author | Number |
---|---|---|---|
CANCER | 2017 |
|
RU2783416C2 |
NEURODEGENERATIVE DISORDERS | 2015 |
|
RU2707191C2 |
AZAANTRACYCLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION | 1996 |
|
RU2159245C2 |
APPLICATION OF ADAMANTANE INDOLE AND THEIR HYDROCHLORIDES AS CHOLINESTERASE INHIBITORS AND NMDA-RECEPTORS BLOCKERS | 2016 |
|
RU2621348C1 |
DERIVATIVES OF 5B-SAPOGENIN AND PSEUDO SAPOGENIN AND APPLICATION FOR DEMENTIA MEDICAL TREATMENT | 2000 |
|
RU2325396C2 |
ISOINDOLINE COMPOSITIONS AND METHODS OF TREATING NEURODEGENERATIVE DISEASE | 2015 |
|
RU2692258C2 |
[1,3]OXAZINES | 2012 |
|
RU2599256C2 |
DIPEPTIDE LINKED MEDICINAL AGENTS | 2009 |
|
RU2578591C2 |
CONJUGATES OF ENGINEERED ANTIBODIES WITH CYSTEINE SUBSTITUTES | 2016 |
|
RU2733740C2 |
ANTIBODY, WHICH RECOGNIZES PEPTIDE T14 ACHE | 2016 |
|
RU2729491C2 |
Authors
Dates
2021-09-24—Published
2017-08-16—Filed